The Cooper Companies, Inc.

COO · NASDAQ · USD

Financials

Annual

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Valuation and market statistics · USD millions unless noted · ratios on the twelve months ending at each period

Line item	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998	FY1997	FY1996	FY1995	FY1994	FY1993	FY1992	FY1991	FY1990	FY1989	FY1988	FY1987	FY1986	FY1985
Valuation
Market cap	$13,899	$20,848	$15,439	$13,491	$20,599	$15,764	$14,378	$12,763	$11,871	$8,698	$7,528	$7,876	$6,281	$4,600	$3,251	$2,256	$1,265	$742	$1,878	$2,566	$2,840	$2,260	$1,356	$810	$712	$507	$373	$352	$462	$167	$68	$82	$19	$39	$81	$93	$58	$145	$204	$538	$545
Enterprise value	$16,572	$23,324	$17,888	$16,116	$21,984	$17,711	$16,115	$14,708	$12,955	$9,931	$8,867	$9,252	$6,567	$4,981	$3,627	$2,864	$2,042	$1,644	$2,751	$3,301	$3,514	$2,384	$1,489	$961	$760	$541	$414	$435	$454	$209	$104	$119	$63	$65	$54	($8)	($34)	$779	$854	$943	$681
P/E (TTM) at period end	37.07×	53.14×	52.48×	34.97×	7.00×	66.12×	30.81×	91.23×	31.83×	31.76×	36.99×	29.19×	21.21×	18.52×	18.53×	20.00×	12.58×	11.59×	–	38.75×	30.96×	24.34×	19.72×	16.58×	19.18×	17.51×	14.87×	8.85×	14.72×	10.07×	680.09×	–	–	–	–	–	–	–	2.99×	–	15.48×
P/S (TTM) at period end	3.40×	5.35×	4.30×	4.08×	7.05×	6.48×	5.42×	5.04×	5.55×	4.42×	4.19×	4.59×	3.96×	3.18×	2.44×	1.95×	1.17×	0.71×	1.98×	2.99×	3.52×	4.61×	3.29×	2.57×	3.04×	2.57×	2.26×	2.39×	3.27×	1.53×	0.70×	0.85×	0.20×	0.62×	2.27×	1.92×	1.10×	0.24×	0.33×	1.17×	1.65×
P/B at period end	1.69×	2.58×	2.04×	1.88×	2.97×	4.12×	3.96×	3.86×	3.74×	3.23×	2.82×	3.06×	2.61×	2.10×	1.68×	1.35×	0.82×	0.52×	1.29×	1.86×	2.23×	4.15×	3.21×	2.60×	2.78×	2.56×	2.27×	2.42×	4.15×	10.93×	–	–	37.82×	0.85×	1.12×	1.08×	0.57×	3.03×	0.79×	2.44×	2.67×
EV / EBITDA (TTM)	15.63×	21.58×	19.86×	18.88×	26.97×	38.36×	19.47×	21.69×	20.98×	19.01×	20.71×	20.81×	15.23×	12.62×	11.13×	10.09×	8.42×	7.86×	21.10×	18.91×	19.05×	18.01×	13.82×	12.27×	11.56×	9.73×	8.77×	11.40×	18.82×	11.88×	9.08×	–	–	–	–	–	–	–	–	–	–
EV / Sales (TTM)	4.05×	5.99×	4.98×	4.87×	7.52×	7.29×	6.07×	5.81×	6.06×	5.05×	4.93×	5.39×	4.14×	3.45×	2.73×	2.47×	1.89×	1.57×	2.89×	3.84×	4.36×	4.86×	3.62×	3.05×	3.24×	2.74×	2.51×	2.96×	3.21×	1.92×	1.07×	1.24×	0.68×	1.03×	1.51×	(0.16×)	(0.65×)	1.27×	1.36×	2.05×	2.06×
Returns
Return on equity	4.6%	4.9%	3.9%	5.4%	42.4%	6.2%	12.9%	4.2%	11.7%	10.2%	7.6%	10.5%	12.3%	11.3%	9.1%	6.8%	6.5%	4.5%	(0.8%)	4.8%	7.2%	17.1%	16.3%	15.7%	14.5%	14.6%	15.3%	27.4%	28.2%	108.5%	–	–	(9380.0%)	(53.8%)	(34.6%)	(2.0%)	(16.0%)	(317.4%)	26.5%	(17.5%)	17.2%
Return on invested capital	4.1%	4.5%	3.8%	4.2%	6.1%	4.8%	10.0%	3.2%	9.5%	7.7%	5.6%	7.1%	10.8%	9.9%	9.0%	7.6%	5.7%	4.7%	–	4.8%	5.9%	14.4%	12.9%	10.8%	12.5%	14.1%	12.7%	13.1%	19.4%	25.0%	12.0%	(7.2%)	(53.0%)	(29.0%)	(67.4%)	–	(141.4%)	3.4%	0.5%	6.0%	13.9%
Dividend yield	–	–	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.1%	0.1%	0.1%	0.2%	0.4%	0.1%	0.1%	0.1%	0.1%	0.1%	0.2%	0.1%	0.2%	0.2%	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Financial health
Current ratio	1.89×	1.91×	1.76×	1.20×	2.00×	1.27×	1.05×	2.03×	2.41×	1.73×	1.48×	1.79×	2.33×	2.51×	2.02×	2.46×	2.87×	2.06×	1.81×	1.65×	1.72×	2.61×	2.23×	1.57×	2.28×	1.73×	2.40×	2.49×	2.04×	1.28×	1.04×	1.03×	1.38×	2.23×	3.36×	4.36×	4.30×	1.24×	0.97×	1.38×	3.16×
Debt / equity	0.30×	0.32×	0.34×	0.39×	0.21×	0.47×	0.50×	0.61×	0.37×	0.49×	0.51×	0.54×	0.14×	0.17×	0.20×	0.36×	0.50×	0.64×	0.60×	0.54×	0.55×	0.30×	0.44×	0.53×	0.27×	0.24×	0.38×	0.62×	0.09×	3.18×	(27.47×)	(12.86×)	107.80×	1.38×	0.69×	0.85×	1.03×	14.42×	2.64×	2.01×	1.28×
Effective tax rate	33.8%	32.6%	28.7%	18.8%	(499.1%)	10.5%	2.2%	57.8%	5.4%	7.0%	4.8%	8.3%	4.9%	9.7%	9.0%	9.3%	12.4%	13.5%	1765.5%	9.7%	15.4%	17.5%	24.0%	25.0%	28.8%	30.2%	32.7%	(150.2%)	(122.0%)	(37.2%)	50.0%	49.5%	(1.2%)	(0.6%)	(0.8%)	75.0%	11.9%	(7.7%)	46.0%	(9.6%)	6.4%
Share count
Diluted shares outstanding	200	200	199	199	199	198	200	199	198	196	197	196	199	197	193	186	182	180	179	190	180	143	133	125	122	116	114	122	103	94	93	83	81	77	69	68	62	62	65	58	56

StatisticsIncome statementBalance sheetCash flowDividendsSegments

Income statement · USD millions

Line item	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014	FY2013	FY2012	FY2011	FY2010	FY2009	FY2008	FY2007	FY2006	FY2005	FY2004	FY2003	FY2002	FY2001	FY2000	FY1999	FY1998	FY1997	FY1996	FY1995	FY1994	FY1993	FY1992	FY1991	FY1990	FY1989	FY1988	FY1987	FY1986	FY1985
Revenue and gross profit
Revenue	$4,237	$4,092	$3,895	$3,593	$3,308	$2,922	$2,431	$2,653	$2,533	$2,139	$1,967	$1,797	$1,718	$1,588	$1,445	$1,331	$1,159	$1,080	$1,047	$951	$859	$807	$490	$412	$315	$235	$197	$165	$147	$142	$109	$97	$96	$93	$63	$36	$48	$53	$611	$628	$460	$331
Cost of revenue	($1,444)	($1,410)	($1,300)	($1,235)	($1,169)	($967)	($896)	($897)	($900)	($773)	($794)	($727)	($626)	($561)	($521)	($526)	($482)	($484)	($437)	($431)	($333)	($310)	($174)	($147)	($116)	($81)	–	–	($51)	–	–	($57)	($61)	($59)	($34)	($16)	($17)	($7)	($293)	($265)	($181)	($112)
Gross profit	$2,793	$2,682	$2,596	$2,358	$2,140	$1,956	$1,535	$1,757	$1,632	$1,366	$1,173	$1,070	$1,092	$1,027	$924	$805	$677	$596	$610	$520	$526	$497	$316	$265	$199	$153	–	–	$96	–	–	$40	$35	$34	$29	$20	$31	$46	$318	$362	$279	$219
Operating expenses
Research and development	($170)	($172)	($155)	($137)	($110)	($93)	($93)	($87)	($85)	($69)	($65)	($70)	($66)	($59)	($52)	($44)	($35)	($33)	($35)	($40)	($35)	($43)	($6)	($6)	($4)	($4)	($3)	($2)	($2)	($2)	($1)	($3)	–	–	–	–	–	–	–	–	–	–
Selling, general and administrative	($1,887)	($1,628)	($1,534)	($1,501)	($1,342)	($1,211)	($992)	($996)	($973)	($799)	($723)	($712)	($683)	($611)	($565)	($513)	($433)	($392)	($429)	($408)	($358)	($298)	($191)	($163)	($127)	($90)	($75)	($62)	($56)	($38)	($30)	($26)	($35)	($53)	($49)	($49)	($43)	($47)	($262)	($312)	($219)	($154)
Total operating expenses	($2,249)	($1,999)	($1,890)	($1,825)	($1,632)	($1,450)	($1,223)	($1,210)	($1,229)	($937)	($849)	($834)	($785)	($721)	($641)	($577)	($487)	($447)	($483)	($474)	($413)	($361)	($199)	($170)	($133)	($99)	–	–	($66)	–	–	($32)	($40)	($57)	($50)	($50)	($44)	($61)	($295)	($354)	($241)	($169)
Total costs and expenses	($3,693)	($3,410)	($3,190)	($3,060)	($2,801)	($2,417)	($2,119)	($2,107)	($2,130)	($1,710)	($1,643)	($1,560)	($1,411)	($1,282)	($1,162)	($1,103)	($969)	($931)	($920)	($905)	($746)	($671)	($373)	($317)	($248)	($180)	($150)	($126)	($117)	($122)	($95)	($89)	($100)	($116)	($84)	($66)	($62)	($67)	($588)	($619)	($422)	($281)
Operating income	$544	$683	$706	$533	$508	$506	$312	$547	$403	$429	$324	$237	$306	$306	$283	$228	$190	$150	$127	$46	$113	$136	$117	$95	$67	$55	$47	$39	$30	$20	$14	$8	($5)	($24)	($21)	($30)	($13)	($15)	$23	$9	$38	$50
Earnings
EBITDA	$928	$1,060	$1,081	$901	$854	$815	$462	$828	$678	$618	$522	$428	$445	$431	$395	$326	$284	$242	$209	$130	$175	$184	$132	$108	$78	$66	$56	$47	$38	$24	$18	$11	($1)	($19)	($19)	($29)	–	($1)	–	–	–	–
Interest income	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Interest expense	($89)	($100)	($114)	($105)	($57)	($23)	($37)	($68)	($83)	($33)	($26)	($18)	($8)	($9)	($12)	($17)	($37)	($44)	($53)	($68)	($59)	($44)	($3)	($3)	–	($2)	($5)	($3)	($25)	($21)	($4)	($11)	($5)	($27)	–	–	–	–	($262)	–	($96)	($6)
Pre-tax income	$462	$566	$582	$413	$475	$492	$266	$477	$332	$394	$296	$216	$297	$312	$275	$193	$124	$115	$74	$1	$73	$108	$112	$90	$65	$52	$42	$33	$23	$22	$12	$0	($9)	($34)	($16)	($25)	($4)	($18)	($141)	$126	($23)	$38
Income tax expense	$108	($192)	($190)	($119)	($90)	$2,453	($28)	($11)	($192)	($21)	($21)	($10)	($25)	($15)	($27)	($17)	($12)	($14)	($10)	($12)	($7)	($17)	($20)	($22)	($16)	($15)	($13)	($11)	$35	$27	$4	($0)	$5	($0)	($0)	($0)	$3	$2	($11)	($58)	($2)	($2)
Net income	$570	$375	$392	$294	$386	$2,945	$238	$467	$140	$373	$274	$204	$270	$296	$248	$175	$113	$101	$64	($11)	$66	$92	$93	$69	$49	$37	$29	$25	$40	$31	$17	$0	($5)	($47)	($25)	($25)	($2)	($16)	($152)	$68	($39)	$35
Per share
Diluted EPS (GAAP)	$2.93	$1.87	$1.96	$1.48	$1.94	$14.79	$1.20	$2.33	$0.7025	$1.88	$1.40	$1.03	$1.38	$1.49	$1.26	$0.9075	$0.6075	$0.5525	$0.355	($0.25)	$1.44	$2.04	$2.59	$2.09	$1.57	$1.22	$1.00	$0.88	$1.31	$1.20	$0.71	$0.005	($0.23)	($2.33)	($1.30)	($1.44)	($0.0999)	($1.05)	($9.80)	$4.23	($2.66)	$2.52
Basic EPS (GAAP)	$2.94	$1.88	$1.97	$1.49	$1.95	$14.95	$1.21	$2.36	$0.7125	$1.91	$1.41	$1.05	$1.40	$1.52	$1.29	$0.935	$0.62	$0.5575	$0.355	($0.25)	$1.49	$2.06	$2.83	$2.20	$1.60	$1.25	$1.02	$0.89	$1.35	$1.20	$0.72	$0.005	($0.23)	($2.33)	($1.30)	($1.44)	($0.0999)	($1.05)	($9.80)	$4.46	($2.66)	$2.52
Basic shares outstanding	195	199	199	198	197	197	196	198	196	196	194	194	192	194	192	188	182	181	180	179	178	165	130	125	122	119	114	113	119	103	93	93	83	81	77	69	68	62	62	61	58	56
Margins
Gross margin	65.9%	65.5%	66.6%	65.6%	64.7%	66.9%	63.1%	66.2%	64.4%	63.9%	59.6%	59.6%	63.5%	64.7%	63.9%	60.5%	58.4%	55.2%	58.2%	54.7%	61.2%	61.6%	64.4%	64.4%	63.3%	65.4%	–	–	65.4%	–	–	41.3%	36.4%	36.6%	46.1%	55.2%	63.9%	87.1%	52.0%	57.7%	60.6%	66.2%
Operating margin	12.8%	16.7%	18.1%	14.8%	15.3%	17.3%	12.8%	20.6%	15.9%	20.1%	16.5%	13.2%	17.8%	19.3%	19.6%	17.1%	16.4%	13.9%	12.1%	4.8%	13.1%	16.8%	23.8%	23.1%	21.2%	23.3%	23.8%	23.5%	20.2%	14.1%	13.1%	8.3%	(5.0%)	(25.4%)	(33.0%)	(85.1%)	(27.6%)	(27.7%)	3.7%	1.4%	8.2%	15.2%
Net margin	13.5%	9.2%	10.1%	8.2%	11.7%	100.8%	9.8%	17.6%	5.5%	17.4%	13.9%	11.3%	15.7%	18.7%	17.2%	13.2%	9.7%	9.3%	6.1%	(1.2%)	7.7%	11.4%	18.9%	16.7%	15.5%	15.8%	14.7%	15.2%	27.0%	22.2%	15.2%	0.1%	(4.9%)	(50.6%)	(39.3%)	(69.9%)	(3.5%)	(30.9%)	(24.8%)	10.9%	(8.4%)	10.6%

Analyst consensus

Buy28 analysts

Bearish · 1 · Hold · 13 · Bullish · 14

Earnings history

	EPS	Estimate
Q4 2024	$1.04	$1.00	Beat
Q1 2025	$0.92	$0.91	Beat
Q2 2025	$0.96	$0.93	Beat
Q3 2025	$1.10	$1.07	Beat
Q4 2025	$1.15	$1.11	Beat
Q1 2026	$1.10	$1.03	Beat
Q2 2026	$1.21	$1.10	Beat
Q3 2026	$1.15	$1.12	Beat

Peers

Company overview

IPO dateJan 21, 1983

CEOAlbert G. White

Employees15,000

SectorHealthcare

IndustryMedical - Instruments & Supplies

CountryUS

ExchangeNASDAQ Global Select

Websitewww.coopercos.com

The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Meanwhile, CooperSurgical is dedicated to women's and family health, providing a wide array of medical devices, fertility treatments, genetic testing, diagnostic tools, and contraceptives to healthcare providers and patients globally. This segment's offerings encompass various surgical and office-based products like PARAGARD (an IUD), uterine manipulators, retractors, and closure devices. It also delivers comprehensive fertility services, including specialized consumables, equipment, embryo services, and preimplantation genetic screening. Established in 1958, The Cooper Companies, Inc. is headquartered in San Ramon, California.

Athenic provides research and information tools for educational purposes only and is not a registered investment adviser or broker-dealer. Nothing on this page is investment advice or a recommendation to buy or sell any security. Market data may be delayed. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal.